Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-04-24FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) from UCB, Inc., expanding or updating its labeling for the drug.
-
FDA approval · 2017-04-24FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), authorizing the extended-release formulation from UCB, for use in epi…
-
FDA approval · 2017-04-24FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) by UCB, Inc., authorizing changes to its labeling and/or indications.
-
FDA approval · 2017-04-20FDA Approved: FELBAMATE — Original Application (Taro Pharmaceuticals U.S.A., inc.)
FDA approves the original ANDA application for Felbamate from Taro Pharmaceuticals U.S.A., enabling a generic version of the antiepileptic d…
-
FDA approval · 2017-04-18FDA Approved: LAMOTRIGINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Lamotrigine by Aurobindo Pharma Limited, enabling a new generic version of lamotrigine.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-04-17Clinical Trial Update: Bioequivalence of Two Different Sources of Eslicarbazepine Acetate [Phase 1]
Phase 1 bioequivalence study comparing eslicarbazepine acetate from two different sources in epilepsy patients to establish similar pharmaco…
-
CLINICAL_TRIALS trial_result · 2017-04-11Clinical Trial Update: A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 [Phase 1]
Phase 1 PET imaging study to measure TAK-935 target occupancy in epilepsy. The trial is completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings
The clinical trial evaluating the StatNet device for EEG recordings in epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery [NA]
A completed clinical trial used functional MRI and EEG to map functional and epileptic brain areas in epilepsy patients before and after sur…
-
FDA label_change · 2017-04-05FDA Approved: TROKENDI XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for TROKENDI XR (topiramate) from Supernus Pharmaceuticals, Inc., leading to labeling updates for th…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug [Phase 4]
A Phase 4 clinical trial update evaluating an investigational drug for treating primary generalized tonic-clonic seizures in epilepsy.
-
FDA approval · 2017-03-29FDA Approved: TOPIRAMATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for Topiramate submitted by Upsher-Smith Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode [Phase 2]
This Phase 2 pharmacokinetic study assessed a single-dose diazepam nasal spray in adults with epilepsy during seizure events.
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions [Phase 1]
Phase 1 bioequivalence study of divalproex sodium 125 mg delayed-release tablets under fasting conditions conducted by Sandoz.
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions [Phase 1]
Phase 1 study completed to assess the relative bioavailability of divalproex sodium 500 mg delayed-release tablets under fed conditions. The…
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions [Phase 1]
Phase 1 study evaluating the relative bioavailability of divalproex sodium 500 mg delayed-release tablets under fasting conditions.
-
FDA approval · 2017-03-24FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Vimpat (lacosamide) submitted by UCB, Inc., updating the product’s label to reflect the requ…
-
FDA approval · 2017-03-24FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA supplemental approval for Neurontin (gabapentin) by Parke-Davis Division of Pfizer Inc.
-
FDA approval · 2017-03-24FDA Approved: GABAPENTIN — Original Application (Rising Pharma Holdings, Inc.)
FDA approves Rising Pharma's original application for gabapentin, a generic version of the anticonvulsant, for the treatment of epilepsy (pa…
-
FDA label_change · 2017-03-23FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) from Novartis Pharmaceuticals Corporation, resulting in a labeling…
-
CLINICAL_TRIALS research · 2017-03-23Clinical Trial Update: Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy [Phase 4]
This clinical trial update discusses a Phase 4 study of clobazam as an adjunctive treatment for adults with refractory focal epilepsy.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery [Phase 2]
Novartis-sponsored Phase 2 trial evaluating BGG492 in individuals with refractory partial seizures undergoing inpatient evaluation for epile…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years [Phase 3]
Phase 3 trial evaluating pregabalin as add-on therapy for partial onset seizures in children aged 4-16; completed with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization
The clinical trial update indicates that the health economic study evaluating the Brain Sentinel GTC Seizure Detection and Information Syste…
-
CLINICAL_TRIALS trial_result · 2017-03-17Clinical Trial Update: Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy [Phase 3]
A Phase 3 trial evaluating Brivaracetam as add-on therapy for adolescents and adults with epilepsy has completed, with results posted in Mar…